Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis

Cancer Cell International

Review

Kiarash Tanha¹  William Chi Shing Cho²  Sadegh Babashah³  Maryam Sahlolbei⁴  Mahdieh Razmi⁵  Fatemeh Tajik⁵  Elmira Gheytanchi⁵  Zahra Madjd⁶  Roya Ghods⁶ 

[1] Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran;Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong Special Administrative Region, China;Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran;Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran;Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran;Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran;Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran;

关键词: Circulating exosomal microRNAs (exomiRs);    Gastrointestinal cancers;    Prognostic value;    Clinicopathological characteristics;    Meta-analysis;   

DOI  :  10.1186/s12935-023-02851-8

 received in 2022-07-05, accepted in 2023-01-12,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundRecent reports suggested that circulating exosomal microRNAs (exomiRs) may serve as non-invasive prediction biomarkers in gastrointestinal (GI) cancers, yet their clinicopathological and prognostic values need to be more clarified. Hence, the present meta-analysis was aimed to quantitatively assess the evidence regarding the association between circulating exomiRs and prognosis in GI cancer patients.MethodsA comprehensive search was carried out in prominent literature databases, including PubMed, ISI Web of Science, Scopus, and Embase. Odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs) were gathered to evaluate the strength of the association. The quality assessment was investigated through the Newcastle-Ottawa Scale (NOS) and publication bias via Eggers’ test and funnel plots.ResultsA total of 47 studies, comprising of 4881 patients, were considered eligible for this meta-analysis. Both up-regulated and down-regulated circulating exomiRs are significantly associated with differentiation (HR = 1.353, P = 0.015; HR = 1.504, P = 0.016), TNM stage (HR = 2.058, P < 0.001; HR = 2.745, P < 0.001), lymph node metastasis (HR = 1.527, P = 0.004; HR = 2.009, P = 0.002), distant metastasis (HR = 2.006, P < 0.001; HR = 2.799, P = 0.002), worse overall survival (OS) (HR = 2.053, P < 0.001; HR = 1.789, P = 0.001) and poorer disease/relapse/progression-free survival (DFS/RFS/PFS) (HR = 2.086, P < 0.001; HR = 1.607, P = 0.001) in GI cancer patients, respectively. In addition, subgroup analyses based on seven subcategories indicated the robustness of the association. The majority of findings were lack of publication bias except for the association between up-regulated exomiRs and OS or DFS/RFS/PFS and for the down-regulated exomiRs and TNM stage.ConclusionThis study supports that up- and down-regulated circulating exomiRs are associated with poorer survival outcomes and could be served as potential prognostic biomarkers in GI cancers. Given the limitations of the current findings, such as significant heterogeneity, more investigations are needed to fully clarify the exomiRs prognostic role.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 6

41116_2022_35_Article_IEq77.gif

41116_2022_35_Article_IEq75.gif

40249_2022_1049_Article_IEq34.gif

Fig. 7

40854_2022_439_Article_IEq324.gif

Fig. 1

Fig. 7

41116_2022_35_Article_IEq14.gif

41116_2022_35_Article_IEq11.gif

41116_2022_35_Article_IEq8.gif